Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07280780
Starting soon Observational

CGM-Based Glycemic Analysis After ESI

NCT07280780 · tracked via the Priya Life Science South Korea tracker
Phase
Observational
Started
2026-08-05
Last updated
2026-08-12

Condition(s) studied

Type 2 Diabetes (T2DM)HyperglycemiaRadicular PainSpinal StenosisIntervertebral Disc Herniation

Investigational drug(s) / intervention(s)

Epidural Steroid InjectionContinuous Glucose Monitoring

Epidural Steroid Injection: Administration of 5 mg Dexamethasone via epidural route (cervical or lumbar) under fluoroscopic guidance.

Continuous Glucose Monitoring: A sensor attached to the upper arm to monitor interstitial glucose levels continuously for 15 days.

Study summary

The goal of this clinical study is to learn how blood glucose levels change after an epidural steroid injection (ESI) with dexamethasone in adults. It will specifically compare the glycemic response between patients with type 2 diabetes and those without diabetes.

The main questions it aims to answer are:

Does the injection cause higher or longer-lasting blood glucose elevation in diabetic patients compared to non-diabetic patients? How do the mean glucose level and Time in Range (TIR) change after the injection in both groups?

Researchers will compare a Type 2 Diabetes group to a Non-Diabetes group to see the differences in glycemic fluctuations using a continuous glucose monitoring (CGM) device.

Participants will:

* Wear a small CGM sensor on their arm for about 15 days to monitor blood glucose levels continuously
* Receive an epidural steroid injection containing 5 mg of dexamethasone on Day 3
* Visit the clinic 3 times (Day 1, Day 3, and Day 15) for sensor attachment, the injection procedure, and data collection

Eligibility

Sex
ALL
Min age
20 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 20 to 60 years. * Patients scheduled for cervical or lumbar epidural steroid injection at the pain clinic. * Patients capable of understanding and using a Continuous Glucose Monitoring (CGM) device. Exclusion Criteria: * Patients currently taking or administering steroid medications. * Patients with Type 1 Diabetes Mellitus. * Patients with Cushing's disease. * Patients who have received an epidural steroid injection within the last 3 months. * Patients with a known allergy to contrast media. * Patients taking anticoagulants or antiplatelet agents. * Patients unable to use a Continuous Glucose Monitoring (CGM) device.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Korea University Anam Hospital Seoul Seoul

More Korea University Anam Hospital trials in South Korea

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07280780 on ClinicalTrials.gov ↗ ← All trials in South Korea